Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base-Reference-Cited by-同舟云学术

Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base

Published:2016-03 Issue:2 Volume:15 Page:136-146
ISSN:1538-4721
Container-title:Brachytherapy
language:en
Short-container-title:Brachytherapy

Author:

Amini Arya,Jones Bernard L.,Jackson Matthew W.,Rusthoven Chad G.,Maroni Paul,Kavanagh Brian D.,Raben David

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference45 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J Clin,2015

2. The role of prevalence in the diagnosis of prostate cancer;Delongchamps;Cancer Control,2006

3. RTOG 0815 Protocol Information Version April 21, 2015. Available at:http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0815. Accessed August 3, 2015.

4. RTOG 0232 Protocol Information Version December 17, 2014. Available at:https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0232. Accessed August 3, 2015.

5. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma;Ragde;Cancer,1998

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaginal Dose Reduction by Changing the Ovoid Loading Pattern in Image Guided Intracavitary Brachytherapy of Cervix;The Journal of Obstetrics and Gynecology of India;2023-11-21

2. Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification;PLOS ONE;2019-04-19

3. Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer;Journal of Contemporary Brachytherapy;2019

4. Predictive value of epithelial-mesenchymal-transition (EMT) signature and PARP-1 in prostate cancer radioresistance;The Prostate;2017-10-23

5. ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer;International Journal of Radiation Oncology*Biology*Physics;2017-07